Department of Stomatology, Zhengzhou People's Hospital Affiliated to Southern Medical University, Zhengzhou, China.
Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2383-9.
The role of Cyfra 21-1 in diagnosing squamous cell carcinoma of head and neck is not yet clear. The present meta-analysis aimed to establish the overall diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma.
After a systematic literature review and selection of English language studies, sensitivity, specificity and other measures of accuracy of Cyfra 21-1 in the diagnosis of head and neck squamous cell carcinoma were pooled using random effects models. Summary receiver operating characteristic curve was used to summarize overall diagnostic performance. Publication bias was examined by Deeks' funnel plot.
Thirteen studies with 2269 subjects met the inclusion criteria for the analysis. The pooled sensitivity and specificity of Cyfra 21-1 for diagnosing head and neck squamous cell carcinoma were 0.51 (95%CI: 0.48-0.54) and 0.97 (95%CI: 0.95-0.98), respectively. The positive likelihood ratio was 10.11 (95%CI: 6.50-15.71), negative likelihood ratio was 0.52 (95%CI: 0.41-0.66) and diagnostic odds ratio was 25.60 (95%CI: 13.39-48.96). The area under the summary receiver operating characteristic curve was 0.94.
The evidence from current meta-analysis suggests Cyfra 21-1 plays a valuable role in the diagnosis of head and neck squamous cell carcinoma with high specificity. The results of tumor marker assays should be interpreted in parallel with clinical findings and the results of conventional tests.
Cyfra 21-1 在诊断头颈部鳞状细胞癌中的作用尚不清楚。本荟萃分析旨在确定 Cyfra 21-1 对头颈部鳞状细胞癌的总体诊断准确性。
经过系统的文献回顾和英文研究选择后，使用随机效应模型汇总 Cyfra 21-1 对头颈部鳞状细胞癌诊断的敏感性、特异性和其他准确性衡量指标。使用汇总受试者工作特征曲线总结总体诊断性能。通过 Deeks 漏斗图检查发表偏倚。
符合分析纳入标准的有 13 项研究，共 2269 例患者。Cyfra 21-1 诊断头颈部鳞状细胞癌的汇总敏感性和特异性分别为 0.51（95%CI：0.48-0.54）和 0.97（95%CI：0.95-0.98）。阳性似然比为 10.11（95%CI：6.50-15.71），阴性似然比为 0.52（95%CI：0.41-0.66），诊断比值比为 25.60（95%CI：13.39-48.96）。汇总受试者工作特征曲线下面积为 0.94。
当前荟萃分析的证据表明，Cyfra 21-1 在诊断头颈部鳞状细胞癌方面具有高特异性，具有重要价值。肿瘤标志物检测结果应与临床发现和常规检测结果并行解释。
